IP Library Granted Patent US 11,384,396
Granted Patent B2
US 11,384,396 · App. 15/683,504 · Granted Jul 12, 2022

DNA conformation (loop structures) in normal and abnormal gene expression

Inventors: Alexandre Akoulitchev (Oxford, GB); Aroul Selvam Ramadass (Oxford, GB); Leonid Leonidovich Nikitenko (London, GB)
Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
C12Q1/6883C12Q1/6809C12Q1/6886C12Q2600/136C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,384,396
App. No.
15/683,504
Granted
Jul 12, 2022
Kind
B2
Abstract

Method of detection or diagnosis of abnormal gene expression in an individual comprising determining in a sample from the individual the presence or absence of a chromosome structure in which two separate regions of the gene have been brought into close proximity, to thereby detect or diagnose whether the individual has abnormal gene expression.

Claims (10)

1. A method of making and detecting a ligated DNA, wherein said ligated DNA is made from a DNA sample from an individual of a specific species, wherein the sequence of the ligated DNA can be predicted, and wherein said method comprises the steps of:

(a) identifying Checkpoint Charlie (CC) marker DNA sequences in the genome of the species by a pattern recognition algorithm that scans the genome's DNA sequence and calculates a reverse algorithmic score based on the weights assigned to each type of nucleotide present in the scanned sequence and the position of the nucleotide relative to a nucleotide in the CC marker, wherein said Checkpoint Charlie (CC) marker DNA sequences are capable of coming together to form a juxtaposition;

(b) cross-linking DNA sequences in the sample which have been brought together in a juxtaposition;

(c) cleaving the cross-linked DNA;

(d) ligating the cleaved DNA to create a ligated DNA not previously present in the sample, wherein the ligated DNA comprises sequence from both of the DNA sequences that formed the juxtaposition; and

(e) detecting the presence of the ligated DNA by identifying the presence of Checkpoint Charlies (CC markers) DNA sequences identified in step (a) in the ligated DNA.

2. A method according to claim 1 , wherein step (e) is carried out by amplifying the ligated DNA by PCR.

3. A method according to claim 1 wherein the DNA is eukaryotic DNA.

4. A method according to claim 1 wherein the DNA is plant, yeast, insect, marsupial, bird or mammalian DNA.

5. A method according to claim 1 wherein the DNA is human or rodent DNA.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2022
From: AKOULITCHEV, ALEXANDRE; RAMADASS, AROUL SELVAM; NIKITENKO, LEONID LEONIDOVICH
To: ISIS INNOVATION LIMITED
Reel/Frame 059968/0098 →
CHANGE OF NAME Recorded May 20, 2022
From: ISIS INNOVATION LIMITED
To: OXFORD UNIVERSITY INNOVATION LIMITED
Reel/Frame 061114/0343 →
Priority Claims (1)
GB 0603251 · Feb 17, 2006 · national
Continuity (2)
Continuation 12279133
Related Publication 20180080081A1 · Mar 22, 2018